Autoantibodies News and Research

RSS

Lupus Research Alliance launches first Translational Bridge Award to accelerate lupus treatments

The Lupus Research Alliance (LRA) is excited to announce the first-ever recipients of the Translational Bridge Award (TBA), established this year to accelerate the translation of groundbreaking research into potential treatments and diagnostics for lupus.

8 Nov 2024

Emerging therapies transform autoimmune hepatitis treatment approaches

Autoimmune hepatitis (AIH) is a chronic, progressive liver disease caused by immune system dysregulation that targets the liver. If untreated, AIH can lead to severe complications, including cirrhosis and liver failure.

6 Nov 2024

Study links nasal autoantibodies to COVID-19 severity prediction

A wide variety of COVID-19 symptoms exist, ranging from mild to severe, and while current strains of the virus generally cause milder symptoms, those with co-morbidities are still at an exponentially greater risk of severe disease.

6 Nov 2024

Genetic and environmental drivers shape early type 1 diabetes risk in children

Researchers from the TEDDY study highlight how specific genetic and environmental factors may drive early autoimmunity linked to type 1 diabetes in children, emphasizing distinct patterns for different autoantibodies.

5 Nov 2024

Lupus Research Alliance announces 33 studies to be presented at ACR Convergence 2024

The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that a total of 33 studies, funded by the organization or supported by its clinical research affiliate Lupus Therapeutics, will be presented at ACR Convergence 2024.

5 Nov 2024

Mortality risk higher for those diagnosed with type 2 diabetes at younger ages

Findings indicate younger-onset type 2 diabetes is associated with higher mortality and complications, highlighting the need for focused healthcare strategies.

4 Nov 2024

Targeted therapy improves pregnancy outcomes

Amongst women who experience recurrent pregnancy loss, around 20% test positive for a specific antibody that targets the mother's own body. A Kobe University-led research team now found a treatment that drastically increases these women's chances of carrying to full-term without complications.

26 Sep 2024

A faster, cheaper method to detect immune autoantibodies in whole blood

Researchers developed a quick and affordable whole-blood assay to detect autoantibodies against type I IFNs, enabling rapid diagnostics for immune disorders. This new method has potential clinical impact by addressing key limitations of current tests.

25 Sep 2024

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

The BLA submission for nipocalimab marks a significant advancement in treating generalized myasthenia gravis, showing improved MG-ADL scores in clinical trials.

From Johnson & Johnson 24 Sep 2024

Lupus Research Alliance announces 2024 Diversity in Lupus Research Award recipients

The Lupus Research Alliance (LRA) is pleased to announce the recipients of the 2024 Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research.

17 Sep 2024

New insight into the causes of autoimmune diseases

Autoimmune diseases are widespread and notoriously difficult to treat. In part, this is because why the immune system attacks its own tissues in patients with these conditions remains poorly understood.

14 Sep 2024

Cancer drug offers life-changing results for severe lupus patient

The team at Charité – Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer medication teclistamab. Not long ago, the 23-year-old was wheelchair-bound due to the autoimmune disease.

6 Sep 2024

Study introduces a novel approach to mapping protein-receptor interactions

One in every three FDA-approved drugs targets a single superfamily of receptors dotting the surfaces of human cells.

28 Aug 2024

Engineered human cardiac tissue reveals how lupus autoantibodies damage the heart

Study demonstrates that autoantibodies in systemic lupus erythematosus (SLE) patients contribute to myocardial injury by binding to and impairing stressed cardiac cells, offering insights into potential therapeutic targets.

25 Aug 2024

Rising IBD incidence highlights need for non-invasive biomarkers in diagnosis

The global burden of inflammatory bowel diseases (IBD), primarily Crohn's disease (CD) and ulcerative colitis (UC), continues to rise. Recent data show incidence rates of up to 17.8 cases per 100,000 person-years for CD and even higher for UC, reaching 28.4 per 100,000 person-years. These diseases primarily affect older populations and vary geographically, with higher prevalence rates in highly developed countries.

23 Aug 2024